RNA Relative Valuation
RNA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RNA is overvalued; if below, it's undervalued.
Historical Valuation
Avidity Biosciences Inc (RNA) is now in the Overvalued zone, suggesting that its current forward PS ratio of 587.65 is considered Overvalued compared with the five-year average of -7.89. The fair price of Avidity Biosciences Inc (RNA) is between 3.53 to 20.20 according to relative valuation methord. Compared to the current price of 34.04 USD , Avidity Biosciences Inc is Overvalued By 68.53%.
Relative Value
Fair Zone
3.53-20.20
Current Price：34.04
68.53%
Overvalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
3.04
P/B
Median3y
2.46
Median5y
2.61
-9.56
FCF Yield
Median3y
-13.46
Median5y
-11.08
Competitors Valuation Multiple
The average P/S ratio for RNA's competitors is 153.26, providing a benchmark for relative valuation. Avidity Biosciences Inc Corp (RNA) exhibits a P/S ratio of 587.65, which is 283.43% above the industry average. Given its robust revenue growth of -55.60%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Avidity Biosciences Inc (RNA) currently overvalued or undervalued?
What is Avidity Biosciences Inc (RNA) fair value?
How does RNA's valuation metrics compare to the industry average?
What is the current P/B ratio for Avidity Biosciences Inc (RNA) as of Jul 19 2025?
What is the current FCF Yield for Avidity Biosciences Inc (RNA) as of Jul 19 2025?
What is the current Forward P/E ratio for Avidity Biosciences Inc (RNA) as of Jul 19 2025?